Epidemics

Regional Health Properties Reports Third Quarter 2023 Financial Results

Collected 93% of Contractual Rent Strong Operator Rent Coverage ATLANTA, GA, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Regional Health Properties,…

1 year ago

Emergex Signs Contract of £1.79M with the UK Department of Health and Social Care’s UK Vaccine Network (“UKVN”) to Advance Its Novel Synthetic T Cell-Priming Set-Point Candidate Against Chikungunya Virus

ABINGDON, United Kingdom, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited (‘Emergex’), a clinical-stage biotechnology company addressing major…

1 year ago

HCA Healthcare Provides Business Outlook Ahead of Investor Day

NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE:HCA) will host its Investor Day today beginning at 8:00 a.m. CT. A team of…

1 year ago

Third Harmonic Bio Announces Third Quarter 2023 Financial Results

On track to file a U.S. Investigational New Drug (IND) application for THB335 and initiate clinical studies in 1H’24 Strong financial…

1 year ago

Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

REDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on…

1 year ago

Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI®(sparsentan) in IgAN and Phase 3 DUPLEX Study…

1 year ago

Jasper Therapeutics to Host Key Opinion Leader Webinar on the Potential of Briquilimab for Chronic Urticaria on October 11, 2023

Company to Discuss Upcoming Briquilimab Clinical Studies in Both Chronic Spontaneous Urticaria and Chronic Inducible UrticariaREDWOOD CITY, Calif., Oct. 09,…

1 year ago

Jasper Therapeutics Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous Urticaria

First Patient Expected to be Dosed by Year-end 2023; Early Data Expected by Mid-2024 Clinical Study in Chronic Inducible Urticaria…

1 year ago

Goodness Growth Holdings and Grown Rogue International Announce the Completed Issuance of Warrants

 Goodness Growth and Grown Rogue each issued warrants to the other to purchase listed shares   Issuances were announced in May…

1 year ago